Current treatments

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial. Merz M et al. Haematologica. 2015 Apr 3. pii: haematol.2015.124347. [Epub ahead of print]. Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Grövdal M et al. Bone Marrow Transplant. 2015 Apr 13.…

AWMSG recommendations on the use of plerixafor

AWMSG has recommended the use of plerixafor (Mozobil®) as an option within NHS Wales in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells in myeloma patients whose cells mobilise poorly. Patients may use plerixafor if they have already failed one complete mobilisation attempt.